GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Peijia Medical Ltd (HKSE:09996) » Definitions » Operating Income

Peijia Medical (HKSE:09996) Operating Income : HK$-294.9 Mil (TTM As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Peijia Medical Operating Income?

Peijia Medical's Operating Income for the six months ended in Jun. 2024 was HK$-92.4 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-294.9 Mil.

Warning Sign:

Peijia Medical Ltd has never been profitable in the past 3 years. It lost money every year.

Operating Margin % is calculated as Operating Income divided by its Revenue. Peijia Medical's Operating Income for the six months ended in Jun. 2024 was HK$-92.4 Mil. Peijia Medical's Revenue for the six months ended in Jun. 2024 was HK$324.3 Mil. Therefore, Peijia Medical's Operating Margin % for the quarter that ended in Jun. 2024 was -28.51%.

Peijia Medical's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Peijia Medical's annualized ROC % for the quarter that ended in Jun. 2024 was -11.30%. Peijia Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -21.22%.


Peijia Medical Operating Income Historical Data

The historical data trend for Peijia Medical's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Peijia Medical Operating Income Chart

Peijia Medical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Income
Get a 7-Day Free Trial -247.44 -248.07 -672.97 -616.12 -454.82

Peijia Medical Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -176.72 -447.76 -252.32 -202.50 -92.44

Peijia Medical Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-294.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Peijia Medical  (HKSE:09996) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Peijia Medical's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=-184.874 * ( 1 - -4.1% )/( (1740.426 + 1666.153)/ 2 )
=-192.453834/1703.2895
=-11.30 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2922.538 - 150.761 - ( 1031.351 - max(0, 168.714 - 1353.543+1031.351))
=1740.426

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2814.057 - 151.78 - ( 996.124 - max(0, 187.786 - 1316.306+996.124))
=1666.153

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Peijia Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Jun. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-147.158/( ( (500.982 + max(171.431, 0)) + (546.449 + max(168.107, 0)) )/ 2 )
=-147.158/( ( 672.413 + 714.556 )/ 2 )
=-147.158/693.4845
=-21.22 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(87.733 + 186.651 + 47.808) - (150.761 + 0 + 0)
=171.431

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(109.898 + 169.186 + 41.098) - (151.78 + 0 + 0.29500000000002)
=168.107

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Peijia Medical's Operating Margin % for the quarter that ended in Jun. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Jun. 2024 )/Revenue (Q: Jun. 2024 )
=-92.437/324.258
=-28.51 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Peijia Medical Operating Income Related Terms

Thank you for viewing the detailed overview of Peijia Medical's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Peijia Medical Business Description

Traded in Other Exchanges
Address
8 Zhongtian Street, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN
Peijia Medical Ltd is focused on the interventional procedural, transcatheter valve therapeutic, and the neurointerventional procedural medical device market in China. The company's product candidates include Transcatheter Aortic Valve Replacement products, Transcatheter Mitral Valve Replacement/Transcatheter Tricuspid Valve Replacement products, Ancillary products, Neurointerventional products, and its product pipeline consists of transcatheter valve therapeutic and neurointerventional products and product candidates. Its operating segments are Transcatheter Valve Therapeutic Business and Neurointerventional Business.
Executives
Jinnius Drive Trust 2103 Interests held jointly with another person
Xinyue International Limited 2103 Interests held jointly with another person
Ye Hong 2103 Interests held jointly with another person
Zhang Ping Ye 2103 Interests held jointly with another person
Zhang Yi 2301 Trustee
Hanlindale Trust 2103 Interests held jointly with another person
Hillhouse Investment Management, Ltd. 2102 Investment manager
Hh Imv Holdings, L.p. 2201 Interest of corporation controlled by you
Hillhouse Fund Iv, L.p. 2201 Interest of corporation controlled by you
Hh Sum-xxiv Holdings Limited 2101 Beneficial owner
Fil Limited 2201 Interest of corporation controlled by you
Pandanus Associates Inc. 2201 Interest of corporation controlled by you
Pandanus Partners L.p. 2201 Interest of corporation controlled by you
Lav Asset Management (hong Kong) Limited 2102 Investment manager
Shi Yi 2201 Interest of corporation controlled by you

Peijia Medical Headlines

No Headlines